Cerivastatin in the treatment of mixed hyperlipidemia: The RIGHT study

American Journal of Cardiology

Volumn 82, Issue 4 B, 1998, Pages 47J-51J

  Farnier, Michel ^a  

^a Point Medical   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERLIPIDEMIA; HYPOLIPEMIA; LIPID METABOLISM; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032572721     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00437-8     Document Type: Conference Paper

References (18)

1. Grundy S.M., Chait A., Brunzell J.D. Familial combined hyperlipidemia workshop. Arteriosclerosis. 7:1987;203-207.
2. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia an appraisal of their efficacy and safety . Eur Heart J. 16:1995;5-13.
3. Chait A., Albers J.J., Brunzell J.D. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest. 10:1980;17-22.
4. Janus E.D., Nicoll A.M., Turner P.R., Magill P., Lewis B. Kinetic bases of the primary hyperlipidaemias studies of apolipoprotein B turnover in genetically defined subjects . Eur J Clin Invest. 10:1980;161-172.
5. Williams G., Monson J.P. Diabetes mellitus and disorders of lipid and intermediary metabolism. Souhamin R.L., Moxham J. Textbook of Medicine. 2nd Edn :1990;739-784 Churchill Livingstone, Edinburgh.
6. Assmann G., Schulte H., Cullen P. New and classical risk factors - the Munster heart study (PROCAM). Eur J Med Res. 2:1997;237-242.
7. Genest J.J. Jr, Martin-Munley S.S., McNamara J.R., Ordovas J.M., Jenner J., Myers R.H., Silberman S.R., Wilson P.W., Salem D.N., Schaefer E.J. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 85:1992;2025-2033.
8. Kane J.P., Havel R.J. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. Scriver C.R., Beaudet A.L., Sly W.S., et al. The Metabolic Basis of Inherited Disease. 6th Edn. 1989;1139 McGraw-Hill, New York.
9. McKenney J.M., Proctor J.D., Harris S., Chinchili V.M. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 271:1994;672-677.
10. Manttari M., Koskinen P., Manninen V., Huttunen J.K., Frick M.H., Nikkila E.A. Effects of gemfibrozil on the concentration and composition of serum lipoproteins. Atherosclerosis. 81:1990;11-17.
11. Illingworth D.R. Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs. 41:1991;151-160.
12. Austin M.A. Plasma triglycerides and coronary heart disease. Arterioscler Thromb Vasc Biol. 11:1991;2-14.
13. Anderson K.M., Castelli W.P., Levy D. Cholesterol and mortality 30 years of follow-up from the Framingham Study . JAMA. 257:1987;2176-2180.
14. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Manttari M., Heinonen O.P., Frick M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study implications for treatment . Circulation. 85:1992;37-45.
15. Larsen M.L., Illingworth D.R. Drug treatment of dyslipoproteinemia. Med Clin N Am. 78:1994;225-245.
16. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;66B-69B.
17. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Keilson L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
18. Bischoff H., Angerbauer R., Bender J., Bischoff E., Fagiotto A., Petzinna D., Pfitzner J., Porter M.C., Schmidt D., Thomas G. Cerivastatin pharmacology of a novel synthetic and high active HMG-CoA reductase inhibitor . Atherosclerosis. 135:1997;119-130.